{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:06:01Z","timestamp":1790651161210,"version":"4.1.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"European Union Next-Generation EU","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}]},{"name":"Institute for Clinical and Experimental Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40266-025-01267-5","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:16:30Z","timestamp":1765286190000},"page":"29-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives"],"prefix":"10.1007","volume":"43","author":[{"given":"Michal","family":"Dubsk\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Soj\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Fejfarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3186-4122","authenticated-orcid":false,"given":"Edward B.","family":"Jude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"1267_CR1","unstructured":"Federation, I.D. IDF Diabetes Atlas. 2025 11th edition]; Available from: https:\/\/diabetesatlas.org."},{"issue":"1","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41582-024-01041-y","volume":"21","author":"MG Savelieff","year":"2025","unstructured":"Savelieff MG, et al. The global and regional burden of diabetic peripheral neuropathy. Nat Rev Neurol. 2025;21(1):17\u201331.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"1267_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","volume":"19","author":"CW Hicks","year":"2019","unstructured":"Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86.","journal-title":"Curr Diab Rep"},{"issue":"3","key":"1267_CR4","first-page":"229","volume":"13","author":"B Andrei Cristian","year":"2018","unstructured":"Andrei Cristian B, Amorin Remus P. Diabetic neuropathy prevalence and its associated risk factors in two representative groups of type 1 and type 2 diabetes mellitus patients from Bihor County. Maedica (Bucur). 2018;13(3):229\u201334.","journal-title":"Maedica (Bucur)"},{"issue":"1","key":"1267_CR5","doi-asserted-by":"publisher","first-page":"14430","DOI":"10.1038\/s41598-024-65495-2","volume":"14","author":"W Perveen","year":"2024","unstructured":"Perveen W, et al. Prevalence of peripheral neuropathy, amputation, and quality of life in patients with diabetes mellitus. Sci Rep. 2024;14(1):14430.","journal-title":"Sci Rep"},{"issue":"1","key":"1267_CR6","doi-asserted-by":"publisher","first-page":"11744","DOI":"10.1038\/s41598-023-39037-1","volume":"13","author":"S Akhtar","year":"2023","unstructured":"Akhtar S, et al. The prevalence of peripheral neuropathy among the patients with diabetes in Pakistan: a systematic review and meta-analysis. Sci Rep. 2023;13(1):11744.","journal-title":"Sci Rep"},{"issue":"1","key":"1267_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42.","journal-title":"Nat Rev Dis Primers"},{"key":"1267_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/DMSO.S252673","volume":"13","author":"S Nakanishi","year":"2020","unstructured":"Nakanishi S, et al. Association between severity of diabetic neuropathy and success in weight loss during hospitalization among Japanese patients with type 2 diabetes: a retrospective observational study. Diabetes Metab Syndr Obes. 2020;13:1669\u201376.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui R, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u201354.","journal-title":"Diabetes Care"},{"key":"1267_CR10","doi-asserted-by":"publisher","first-page":"1265372","DOI":"10.3389\/fendo.2023.1265372","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 2023;14:1265372.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1267_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212574","volume":"14","author":"X Liu","year":"2019","unstructured":"Liu X, et al. The risk factors for diabetic peripheral neuropathy: a meta-analysis. PLoS ONE. 2019;14(2):e0212574.","journal-title":"PLoS ONE"},{"issue":"2","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","volume":"9","author":"CMO Volpe","year":"2018","unstructured":"Volpe CMO, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):119.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1267_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/jnc.15606","volume":"162","author":"P Yuan","year":"2022","unstructured":"Yuan P, et al. Poly (ADP-ribose) polymerase 1-mediated defective mitophagy contributes to painful diabetic neuropathy in the db\/db model. J Neurochem. 2022;162(3):276\u201389.","journal-title":"J Neurochem"},{"key":"1267_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.973058","volume":"13","author":"D Pan","year":"2022","unstructured":"Pan D, Xu L, Guo M. The role of protein kinase C in diabetic microvascular complications. Front Endocrinol (Lausanne). 2022;13:973058.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1267_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s001250050911","volume":"41","author":"EB Jude","year":"1998","unstructured":"Jude EB, et al. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia. 1998;41(3):330\u20136.","journal-title":"Diabetologia"},{"issue":"9","key":"1267_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101582","volume":"69","author":"B Zaino","year":"2023","unstructured":"Zaino B, Goel R, Devaragudi S, Prakash A, Vaghamashi Y, Sethi Y, et al. Diabetic neuropathy: pathogenesis and evolving principles of management. Dis Mon. 2023;69(9):101582. https:\/\/doi.org\/10.1016\/j.disamonth.2023.101582.","journal-title":"Dis Mon"},{"key":"1267_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/life12081185","author":"S Smith","year":"2022","unstructured":"Smith S, et al. Prevention and management strategies for diabetic neuropathy. Life. 2022. https:\/\/doi.org\/10.3390\/life12081185.","journal-title":"Life"},{"issue":"4","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10286-019-00607-x","volume":"29","author":"LA Zilliox","year":"2019","unstructured":"Zilliox LA, Russell JW. Physical activity and dietary interventions in diabetic neuropathy: a systematic review. Clin Auton Res. 2019;29(4):443\u201355.","journal-title":"Clin Auton Res"},{"issue":"5","key":"1267_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2015.8","volume":"5","author":"AE Bunner","year":"2015","unstructured":"Bunner AE, et al. A dietary intervention for chronic diabetic neuropathy pain: a randomized controlled pilot study. Nutr Diabetes. 2015;5(5):e158.","journal-title":"Nutr Diabetes"},{"issue":"8","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11606-015-3354-y","volume":"30","author":"C Clair","year":"2015","unstructured":"Clair C, et al. The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis. J Gen Intern Med. 2015;30(8):1193\u2013203.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3349\/ymj.2023.0355","volume":"65","author":"Y Cho","year":"2024","unstructured":"Cho Y, et al. The association of smoking status with diabetic microvascular complications in Korean patients with type 2 diabetes. Yonsei Med J. 2024;65(8):427\u201333.","journal-title":"Yonsei Med J"},{"issue":"11","key":"1267_CR22","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"2","key":"1267_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MED.0b013e328014979e","volume":"14","author":"AJ Boulton","year":"2007","unstructured":"Boulton AJ. Diabetic neuropathy: classification, measurement and treatment. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):141\u20135. https:\/\/doi.org\/10.1097\/MED.0b013e328014979e.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1267_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.diabres.2017.04.013","volume":"127","author":"A Ibrahim","year":"2017","unstructured":"Ibrahim A. IDF clinical practice recommendation on the diabetic foot: a guide for healthcare professionals. Diabetes Res Clin Pract. 2017;127:285\u20137.","journal-title":"Diabetes Res Clin Pract"},{"key":"1267_CR25","doi-asserted-by":"publisher","first-page":"8787261","DOI":"10.1155\/2017\/8787261","volume":"2017","author":"F Wang","year":"2017","unstructured":"Wang F, et al. Diagnostic accuracy of monofilament tests for detecting diabetic peripheral neuropathy: a systematic review and meta-analysis. J Diabetes Res. 2017;2017:8787261.","journal-title":"J Diabetes Res"},{"issue":"6","key":"1267_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082193","volume":"14","author":"S Chattopadhyay","year":"2024","unstructured":"Chattopadhyay S, et al. Can the 128-Hz tuning fork be an alternative to the biothesiometer for diabetic peripheral neuropathy screening? A cross-sectional study in a tertiary hospital in East India. BMJ Open. 2024;14(6):e082193.","journal-title":"BMJ Open"},{"key":"1267_CR27","doi-asserted-by":"publisher","unstructured":"Pleven, S., et al., Screening for diabetic peripheral neuropathy: subjective versus objective measures. Int J Low Extrem Wounds. 2024;15347346241295461. https:\/\/doi.org\/10.1177\/15347346241295461.","DOI":"10.1177\/15347346241295461"},{"issue":"10","key":"1267_CR28","volume":"16","author":"S Kelshikar","year":"2024","unstructured":"Kelshikar S, et al. The role of a biothesiometer in early detection and management of diabetic neuropathy. Cureus. 2024;16(10):e70588.","journal-title":"Cureus"},{"issue":"6","key":"1267_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2337\/diacare.23.6.750","volume":"23","author":"JW Meijer","year":"2000","unstructured":"Meijer JW, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care. 2000;23(6):750\u20133.","journal-title":"Diabetes Care"},{"issue":"1","key":"1267_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/jdr\/5902036","volume":"2024","author":"M Mogilevskaya","year":"2024","unstructured":"Mogilevskaya M, Gaviria-Carrillo M, Feliciano-Alfonso JE, Barragan AM, Calderon-Ospina CA, Nava-Mesa MO. Diagnostic accuracy of screening tests for diabetic peripheral neuropathy: an umbrella review. J Diabetes Res. 2024;2024(1):5902036. https:\/\/doi.org\/10.1155\/jdr\/5902036.","journal-title":"J Diabetes Res"},{"issue":"Suppl 1","key":"1267_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000052074","volume":"41","author":"V Bril","year":"1999","unstructured":"Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999;41(Suppl 1):8\u201313.","journal-title":"Eur Neurol"},{"issue":"10","key":"1267_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138224","volume":"10","author":"D Selvarajah","year":"2015","unstructured":"Selvarajah D, et al. SUDOSCAN: a simple, rapid, and objective method with potential for screening for diabetic peripheral neuropathy. PLoS ONE. 2015;10(10):e0138224.","journal-title":"PLoS ONE"},{"issue":"12","key":"1267_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/dme.12536","volume":"31","author":"G Ponirakis","year":"2014","unstructured":"Ponirakis G, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med. 2014;31(12):1673\u201380.","journal-title":"Diabet Med"},{"key":"1267_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1369699","volume":"15","author":"OS Purwanti","year":"2024","unstructured":"Purwanti OS, Nursalam N, Pandin MGR. Early detection of diabetic neuropathy based on health belief model: a scoping review. Front Endocrinol (Lausanne). 2024;15:1369699. https:\/\/doi.org\/10.3389\/fendo.2024.1369699.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1267_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1715163514561055","volume":"148","author":"S Poulose","year":"2015","unstructured":"Poulose S, et al. Usefulness of the NC-stat DPNCheck nerve conduction test in a community pharmacy as an educational tool for patients with diabetes. Can Pharm J (Ott). 2015;148(1):17\u201320.","journal-title":"Can Pharm J (Ott)"},{"issue":"1","key":"1267_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13300-019-00738-4","volume":"11","author":"N Papanas","year":"2020","unstructured":"Papanas N, et al. The diagnostic utility of vibratip for distal symmetrical polyneuropathy in type 2 diabetes mellitus. Diabetes Ther. 2020;11(1):341\u20136.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1267_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1534734621994058","volume":"22","author":"A Tentolouris","year":"2023","unstructured":"Tentolouris A, Tentolouris N, Eleftheriadou I, Jude EB. The performance and interrater agreement of vibration perception for the diagnosis of loss of protective sensation in people with diabetes mellitus. Int J Low Extrem Wounds. 2023;22(1):72\u20136. https:\/\/doi.org\/10.1177\/1534734621994058.","journal-title":"Int J Low Extrem Wounds"},{"issue":"7604","key":"1267_CR38","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bmj.39192.488125.BE","volume":"334","author":"G Lauria","year":"2007","unstructured":"Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ. 2007;334(7604):1159\u201362.","journal-title":"BMJ"},{"key":"1267_CR39","doi-asserted-by":"publisher","DOI":"10.31744\/einstein_journal\/2022MD8044","volume":"20","author":"I Raicher","year":"2022","unstructured":"Raicher I, et al. Investigation of nerve fibers in the skin by biopsy: technical aspects, indications, and contribution to diagnosis of small-fiber neuropathy. Einstein (S\u00e3o Paulo). 2022;20:eMD8044.","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"1267_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2024.1485420","volume":"5","author":"G Sloan","year":"2024","unstructured":"Sloan G, Donatien P, Privitera R, Shillo P, Caunt S, Selvarajah D, et al. Vascular and nerve biomarkers in thigh skin biopsies differentiate painful from painless diabetic peripheral neuropathy. Front Pain Res. 2024;5:1485420. https:\/\/doi.org\/10.3389\/fpain.2024.1485420.","journal-title":"Front Pain Res"},{"issue":"2","key":"1267_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3803\/EnM.2016.31.2.230","volume":"31","author":"JC Won","year":"2016","unstructured":"Won JC, Park TS. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab. 2016;31(2):230\u20138. https:\/\/doi.org\/10.3803\/EnM.2016.31.2.230.","journal-title":"Endocrinol Metab"},{"issue":"1","key":"1267_CR42","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41598-020-60422-7","volume":"10","author":"A Kalteniece","year":"2020","unstructured":"Kalteniece A, et al. Corneal confocal microscopy detects small nerve fibre damage in patients with painful diabetic neuropathy. Sci Rep. 2020;10(1):3371.","journal-title":"Sci Rep"},{"issue":"1","key":"1267_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jdi.13643","volume":"13","author":"H Gad","year":"2022","unstructured":"Gad H, et al. Corneal confocal microscopy for the diagnosis of diabetic peripheral neuropathy: a systematic review and meta-analysis. J Diabetes Investig. 2022;13(1):134\u201347.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"1267_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/dc20-1482","volume":"44","author":"M Ferdousi","year":"2021","unstructured":"Ferdousi M, et al. Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: a corneal confocal microscopy study. Diabetes Care. 2021;44(1):150\u20136.","journal-title":"Diabetes Care"},{"issue":"8","key":"1267_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1055\/s-0042-1756169","volume":"80","author":"RA Malik","year":"2022","unstructured":"Malik RA. Corneal confocal microscopy for the assessment of diabetic neuropathy and beyond in Brazil. Arq Neuropsiquiatr. 2022;80(8):767\u20139.","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"1267_CR46","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.2337\/dc21-0476","volume":"44","author":"BA Perkins","year":"2021","unstructured":"Perkins BA, et al. Corneal confocal microscopy predicts the development of diabetic neuropathy: a longitudinal diagnostic multinational consortium study. Diabetes Care. 2021;44(9):2107\u201314.","journal-title":"Diabetes Care"},{"issue":"1","key":"1267_CR47","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41598-021-81302-8","volume":"11","author":"S Dhage","year":"2021","unstructured":"Dhage S, et al. Corneal confocal microscopy identifies small fibre damage and progression of diabetic neuropathy. Sci Rep. 2021;11(1):1859.","journal-title":"Sci Rep"},{"issue":"4","key":"1267_CR48","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5603\/ep.99842","volume":"75","author":"C Zhang","year":"2024","unstructured":"Zhang C, et al. Application and progress of corneal confocal microscopy in the evaluation of diabetes-related peripheral neuropathy. Endokrynol Pol. 2024;75(4):395\u2013402.","journal-title":"Endokrynol Pol"},{"issue":"9","key":"1267_CR49","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.clinthera.2021.04.003","volume":"43","author":"IN Petropoulos","year":"2021","unstructured":"Petropoulos IN, Ponirakis G, Ferdousi M, Azmi S, Kalteniece A, Khan A, et al. Corneal confocal microscopy: a biomarker for diabetic peripheral neuropathy. Clin Ther. 2021;43(9):1457\u201375. https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.003.","journal-title":"Clin Ther"},{"key":"1267_CR50","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2147\/OPTH.S519705","volume":"19","author":"A Ramirez-Miranda","year":"2025","unstructured":"Ramirez-Miranda A, et al. In vivo confocal microscopy for corneal and ocular surface pathologies: a comprehensive review. Clin Ophthalmol. 2025;19:1817\u201334.","journal-title":"Clin Ophthalmol"},{"issue":"Supplement","key":"1267_CR51","first-page":"S329","volume":"65","author":"D Narasimhaiah","year":"2022","unstructured":"Narasimhaiah D, Mahadevan A. Role of skin punch biopsy in diagnosis of small fiber neuropathy\u2014a review for the neuropathologist. Indian J Pathol Microbiol. 2022;65(Supplement):S329\u201336.","journal-title":"Indian J Pathol Microbiol"},{"issue":"10","key":"1267_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101213","volume":"4","author":"Z Guan","year":"2023","unstructured":"Guan Z, Li H, Liu R, Cai C, Liu Y, Li J, et al. Artificial intelligence in diabetes management: advancements, opportunities, and challenges. Cell Reports Medicine. 2023;4(10):101213. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101213.","journal-title":"Cell Reports Medicine"},{"issue":"3","key":"1267_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.23736\/S0392-9590.23.05008-3","volume":"42","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Machine learning models for diabetic neuropathy diagnosis using microcirculatory parameters in type 2 diabetes patients. Int Angiol. 2023;42(3):191\u2013200.","journal-title":"Int Angiol"},{"issue":"10","key":"1267_CR54","first-page":"1922","volume":"40","author":"M Jabara","year":"2024","unstructured":"Jabara M, et al. Artificial intelligence-based digital biomarkers for type 2 diabetes: a review. Can J Cardiol. 2024;40(10):1922\u201333.","journal-title":"Can J Cardiol"},{"key":"1267_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1325434","volume":"15","author":"H Guan","year":"2024","unstructured":"Guan H, Wang Y, Niu P, Zhang Y, Miao R, Fang X, et al. The role of machine learning in advancing diabetic foot: a review. Front Endocrinol (Lausanne). 2024;15:1325434. https:\/\/doi.org\/10.3389\/fendo.2024.1325434.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1267_CR56","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.2337\/dc20-2012","volume":"44","author":"T Salahouddin","year":"2021","unstructured":"Salahouddin T, et al. Artificial intelligence-based classification of diabetic peripheral neuropathy from corneal confocal microscopy images. Diabetes Care. 2021;44(7):e151\u20133.","journal-title":"Diabetes Care"},{"key":"1267_CR57","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice, C., 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. Diabetes Care, 2025. 48(Supplement_1): p. S252-S265.","DOI":"10.2337\/dc25-S012"},{"key":"1267_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1614657","volume":"16","author":"M Sun","year":"2025","unstructured":"Sun M, Sun X, Wang F, Liu L. Machine learning-based prediction of diabetic peripheral neuropathy: model development and clinical validation. Front Endocrinol (Lausanne). 2025;16:1614657. https:\/\/doi.org\/10.3389\/fendo.2025.1614657.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1267_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051075","author":"G Sartore","year":"2025","unstructured":"Sartore G, et al. Artificial intelligence algorithm to screen for diabetic neuropathy: a pilot study. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13051075.","journal-title":"Biomedicines"},{"issue":"5","key":"1267_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2337\/dc09-1941","volume":"33","author":"JW Albers","year":"2010","unstructured":"Albers JW, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care. 2010;33(5):1090\u20136.","journal-title":"Diabetes Care"},{"issue":"9","key":"1267_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11892-014-0528-7","volume":"14","author":"L Ang","year":"2014","unstructured":"Ang L, et al. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.","journal-title":"Curr Diab Rep"},{"issue":"11","key":"1267_CR62","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P Gaede","year":"2016","unstructured":"Gaede P, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298\u2013307.","journal-title":"Diabetologia"},{"issue":"1","key":"1267_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","volume":"98","author":"R Price","year":"2022","unstructured":"Price R, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology. 2022;98(1):31\u201343.","journal-title":"Neurology"},{"key":"1267_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00285","volume":"8","author":"LC Rolim","year":"2017","unstructured":"Rolim LC, et al. A systematic review of treatment of painful diabetic neuropathy by pain phenotype versus treatment based on medical comorbidities. Front Neurol. 2017;8:285. https:\/\/doi.org\/10.3389\/fneur.2017.00285.","journal-title":"Front Neurol"},{"issue":"10353","key":"1267_CR65","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","volume":"400","author":"S Tesfaye","year":"2022","unstructured":"Tesfaye S, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. 2022;400(10353):680\u201390.","journal-title":"Lancet"},{"issue":"12","key":"1267_CR66","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/BF00400603","volume":"38","author":"D Ziegler","year":"1995","unstructured":"Ziegler D, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425\u201333.","journal-title":"Diabetologia"},{"issue":"3","key":"1267_CR67","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2337\/diacare.26.3.770","volume":"26","author":"AS Ametov","year":"2003","unstructured":"Ametov AS, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770\u20136.","journal-title":"Diabetes Care"},{"issue":"2","key":"1267_CR68","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jdiacomp.2015.10.018","volume":"30","author":"D Ziegler","year":"2016","unstructured":"Ziegler D, et al. Predictors of improvement and progression of diabetic polyneuropathy following treatment with alpha-lipoic acid for 4 years in the NATHAN 1 trial. J Diabetes Complications. 2016;30(2):350\u20136.","journal-title":"J Diabetes Complications"},{"issue":"3","key":"1267_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/10715769900300721","volume":"31","author":"M Reljanovic","year":"1999","unstructured":"Reljanovic M, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171\u20139.","journal-title":"Free Radic Res"},{"issue":"11","key":"1267_CR70","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.2337\/dc06-1216","volume":"29","author":"D Ziegler","year":"2006","unstructured":"Ziegler D, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365\u201370.","journal-title":"Diabetes Care"},{"issue":"10","key":"1267_CR71","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1055\/s-2008-1065351","volume":"116","author":"H Stracke","year":"2008","unstructured":"Stracke H, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600\u20135.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"1267_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5414\/CPP43071","volume":"43","author":"E Haupt","year":"2005","unstructured":"Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy\u2014a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther. 2005;43(2):71\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"1267_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057142","volume":"12","author":"GJ Bonhof","year":"2022","unstructured":"Bonhof GJ, et al. BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open. 2022;12(2):e057142.","journal-title":"BMJ Open"},{"issue":"1","key":"1267_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/diacare.28.1.89","volume":"28","author":"AA Sima","year":"2005","unstructured":"Sima AA, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005;28(1):89\u201394.","journal-title":"Diabetes Care"},{"issue":"1","key":"1267_CR75","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2337\/dc07-0931","volume":"31","author":"M Tao","year":"2008","unstructured":"Tao M, et al. Relationship of polyunsaturated fatty acid intake to peripheral neuropathy among adults with diabetes in the National Health and Nutrition Examination Survey (NHANES) 1999 2004. Diabetes Care. 2008;31(1):93\u20135.","journal-title":"Diabetes Care"},{"key":"1267_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040761","author":"AM Duran","year":"2022","unstructured":"Duran AM, et al. Dietary omega-3 polyunsaturated fatty-acid supplementation upregulates protective cellular pathways in patients with type 2 diabetes exhibiting improvement in painful diabetic Neuropathy. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14040761.","journal-title":"Nutrients"},{"issue":"Suppl 1","key":"1267_CR77","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/j.diabres.2007.01.069","volume":"77","author":"K Matsuoka","year":"2007","unstructured":"Matsuoka K, et al. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT). Diabetes Res Clin Pract. 2007;77(Suppl 1):S263\u20138.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1267_CR78","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc09-0545","volume":"32","author":"D Ziegler","year":"2009","unstructured":"Ziegler D, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479\u201384.","journal-title":"Diabetes Care"},{"key":"1267_CR79","doi-asserted-by":"publisher","unstructured":"Pankiv, I. Clinical efficacy of actovegin in complex treatment of patients with diabetes mellitus type 2 with diabetic polyneuropathy against arterial hypertension. Int J Endocrinol (Ukraine). 2022;30\u201331. https:\/\/doi.org\/10.22141\/2224-0721.2.50.2013.84259.","DOI":"10.22141\/2224-0721.2.50.2013.84259"},{"issue":"Suppl 2","key":"1267_CR80","first-page":"S255","volume":"31","author":"D Ziegler","year":"2008","unstructured":"Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care. 2008;31(Suppl 2):S255\u201361.","journal-title":"Diabetes Care"},{"issue":"7","key":"1267_CR81","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.2337\/dc07-2105","volume":"31","author":"R Freeman","year":"2008","unstructured":"Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31(7):1448\u201354. https:\/\/doi.org\/10.2337\/dc07-2105.","journal-title":"Diabetes Care"},{"issue":"11","key":"1267_CR82","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2018.1509304","volume":"34","author":"B Parsons","year":"2018","unstructured":"Parsons B, et al. The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2018;34(11):2015\u201322.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1267_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clinthera.2011.02.007","volume":"33","author":"YZ Guan","year":"2011","unstructured":"Guan YZ, et al. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Ther. 2011;33(2):159\u201366.","journal-title":"Clin Ther"},{"issue":"5","key":"1267_CR84","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/AJP.0b013e31829ea1a1","volume":"30","author":"P Raskin","year":"2014","unstructured":"Raskin P, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain. 2014;30(5):379\u201390.","journal-title":"Clin J Pain"},{"issue":"3","key":"1267_CR85","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1753-0407.12585","volume":"10","author":"Y Mu","year":"2018","unstructured":"Mu Y, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized placebo-controlled trial. J Diabetes. 2018;10(3):256\u201365.","journal-title":"J Diabetes"},{"issue":"1","key":"1267_CR86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","volume":"28","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109\u201316. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03152.x.","journal-title":"Diabet Med"},{"issue":"2","key":"1267_CR87","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","volume":"66","author":"KC Gorson","year":"1999","unstructured":"Gorson KC, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66(2):251\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1267_CR88","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.diabres.2012.03.010","volume":"97","author":"D Sandercock","year":"2012","unstructured":"Sandercock D, et al. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract. 2012;97(3):438\u201345.","journal-title":"Diabetes Res Clin Pract"},{"issue":"21","key":"1267_CR89","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831\u20136.","journal-title":"JAMA"},{"key":"1267_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ph16071017","author":"M Rakusa","year":"2023","unstructured":"Rakusa M, et al. Efficacy of pregabalin and duloxetine in patients with painful diabetic peripheral neuropathy (PDPN): a multi-centre phase IV Clinical Trial-BLOSSOM. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16071017.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"1267_CR91","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411\u201320.","journal-title":"Neurology"},{"issue":"2","key":"1267_CR92","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1517\/14656566.7.2.215","volume":"7","author":"TR Smith","year":"2006","unstructured":"Smith TR. Duloxetine in diabetic neuropathy. Expert Opin Pharmacother. 2006;7(2):215\u201323. https:\/\/doi.org\/10.1517\/14656566.7.2.215.","journal-title":"Expert Opin Pharmacother"},{"key":"1267_CR93","first-page":"343","volume":"5","author":"MJ Ormseth","year":"2011","unstructured":"Ormseth MJ, Scholz BA, Boomershine CS. Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence. 2011;5:343\u201356.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"1267_CR94","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.pain.2004.05.010","volume":"110","author":"MC Rowbotham","year":"2004","unstructured":"Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697\u2013706. https:\/\/doi.org\/10.1016\/j.pain.2004.05.010.","journal-title":"Pain"},{"issue":"2","key":"1267_CR95","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","volume":"3","author":"DA Simpson","year":"2001","unstructured":"Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001;3(2):53\u201362. https:\/\/doi.org\/10.1097\/00131402-200112000-00002.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"4","key":"1267_CR96","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.37.4.589","volume":"37","author":"MB Max","year":"1987","unstructured":"Max MB, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589\u201396.","journal-title":"Neurology"},{"key":"1267_CR97","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1081792","volume":"2018","author":"A Tedeschi","year":"2018","unstructured":"Tedeschi A, De Bellis A, Francia P, Bernini A, Perini M, Salutini E, et al. Tapentadol prolonged release reduces the severe chronic ischaemic pain and improves the quality of life in patients with type 2 diabetes. J Diabetes Res. 2018;2018:1081792. https:\/\/doi.org\/10.1155\/2018\/1081792.","journal-title":"J Diabetes Res"},{"issue":"1","key":"1267_CR98","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1185\/03007995.2010.537589","volume":"27","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1267_CR99","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.50.6.1842","volume":"50","author":"Y Harati","year":"1998","unstructured":"Harati Y, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842\u20136.","journal-title":"Neurology"},{"issue":"6","key":"1267_CR100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/01.nrl.0000144733.61110.25","volume":"10","author":"C Gooch","year":"2004","unstructured":"Gooch C, Podwall D. The diabetic neuropathies. Neurologist. 2004;10(6):311\u201322.","journal-title":"Neurologist"},{"issue":"1","key":"1267_CR101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1185\/030079906X162674","volume":"23","author":"R Freeman","year":"2007","unstructured":"Freeman R, et al. Randomized study of tramadol\/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23(1):147\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1267_CR102","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","volume":"60","author":"JS Gimbel","year":"2003","unstructured":"Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60(6):927\u201334.","journal-title":"Neurology"},{"issue":"1-2","key":"1267_CR103","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","volume":"105","author":"CP Watson","year":"2003","unstructured":"Watson CP, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105(1\u20132):71\u20138.","journal-title":"Pain"},{"issue":"3","key":"1267_CR104","first-page":"227","volume":"94","author":"MJ Snyder","year":"2016","unstructured":"Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016;94(3):227\u201334.","journal-title":"Am Fam Physician"},{"issue":"18","key":"1267_CR105","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1517\/14656566.2014.972935","volume":"15","author":"N Papanas","year":"2014","unstructured":"Papanas N, Ziegler D. Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721\u201331.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1267_CR106","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/jpgm.jpgm_310_24","volume":"70","author":"U Pingali","year":"2024","unstructured":"Pingali U, et al. A randomized, double-blind, placebo controlled study to evaluate the effect of alpha-lipoic acid on inhibition of ADP-and collagen-induced platelet aggregation ex vivo in diabetic neuropathy patients on gabapentin or pregabalin. J Postgrad Med. 2024;70(4):191\u20137.","journal-title":"J Postgrad Med"},{"issue":"9","key":"1267_CR107","first-page":"786","volume":"93","author":"S Bartkoski","year":"2016","unstructured":"Bartkoski S, Day M. Alpha-lipoic acid for treatment of diabetic peripheral neuropathy. Am Fam Physician. 2016;93(9):786.","journal-title":"Am Fam Physician"},{"key":"1267_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163634","author":"RY Hsieh","year":"2023","unstructured":"Hsieh RY, et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: a meta-analysis and systematic review. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15163634.","journal-title":"Nutrients"},{"issue":"1","key":"1267_CR109","first-page":"CD012967","volume":"1","author":"C Baicus","year":"2024","unstructured":"Baicus C, et al. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2024;1(1):CD012967.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1267_CR110","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nm834","volume":"9","author":"HP Hammes","year":"2003","unstructured":"Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9(3):294\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"1267_CR111","first-page":"CD011265","volume":"6","author":"LC Rolim","year":"2019","unstructured":"Rolim LC, et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2019;6(6):CD011265.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1267_CR112","first-page":"164","volume":"8","author":"BP Ander","year":"2003","unstructured":"Ander BP, et al. Polyunsaturated fatty acids and their effects on cardiovascular disease. Exp Clin Cardiol. 2003;8(4):164\u201372.","journal-title":"Exp Clin Cardiol"},{"issue":"7-9","key":"1267_CR113","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/ars.2021.0155","volume":"37","author":"AE Rumora","year":"2022","unstructured":"Rumora AE, Kim B, Feldman EL. A role for fatty acids in peripheral neuropathy associated with type 2 diabetes and prediabetes. Antioxid Redox Signal. 2022;37(7\u20139):560\u201377. https:\/\/doi.org\/10.1089\/ars.2021.0155.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"1267_CR114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1464-5491.1990.tb01397.x","volume":"7","author":"GA Jamal","year":"1990","unstructured":"Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990;7(4):319\u201323.","journal-title":"Diabet Med"},{"issue":"4","key":"1267_CR115","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4093\/dmj.2019.0099","volume":"44","author":"JC Won","year":"2020","unstructured":"Won JC, et al. Gamma-linolenic acid versus alpha-lipoic acid for treating painful diabetic neuropathy in adults: a 12-week, double-placebo, randomized, noninferiority trial. Diabetes Metab J. 2020;44(4):542\u201354.","journal-title":"Diabetes Metab J"},{"issue":"5","key":"1267_CR116","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jdiacomp.2009.07.005","volume":"24","author":"KE Schemmel","year":"2010","unstructured":"Schemmel KE, Padiyara RS, D\u2019Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications. 2010;24(5):354\u201360. https:\/\/doi.org\/10.1016\/j.jdiacomp.2009.07.005.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"1267_CR117","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/1673-5374.177745","volume":"11","author":"QR Li","year":"2016","unstructured":"Li QR, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016;11(2):345\u201351.","journal-title":"Neural Regen Res"},{"issue":"7","key":"1267_CR118","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.2337\/dc05-2370","volume":"29","author":"N Hotta","year":"2006","unstructured":"Hotta N, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29(7):1538\u201344.","journal-title":"Diabetes Care"},{"issue":"1","key":"1267_CR119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13300-018-0550-x","volume":"10","author":"S Azmi","year":"2019","unstructured":"Azmi S, et al. Pregabalin in the management of painful diabetic neuropathy: a narrative review. Diabetes Ther. 2019;10(1):35\u201356.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1267_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110765","volume":"206","author":"S Tesfaye","year":"2023","unstructured":"Tesfaye S, Kempler P. Conventional management and current guidelines for painful diabetic neuropathy. Diabetes Res Clin Pract. 2023;206(1):110765.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1267_CR121","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00002508-200112000-00002","volume":"17","author":"MA Mellegers","year":"2001","unstructured":"Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001;17(4):284\u201395.","journal-title":"Clin J Pain"},{"key":"1267_CR122","doi-asserted-by":"publisher","unstructured":"Eibye, E., et al., Implementation of pharmacist driven gabapentinoid titration for diabetic peripheral neuropathy in a primary care setting. J Pain Palliat Care Pharmacother. 2025;39(1):162\u2013169. https:\/\/doi.org\/10.1080\/15360288.2024.2421527.","DOI":"10.1080\/15360288.2024.2421527"},{"issue":"1","key":"1267_CR123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13643-023-02185-6","volume":"12","author":"CS Wu","year":"2023","unstructured":"Wu CS, et al. Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Syst Rev. 2023;12(1):53.","journal-title":"Syst Rev"},{"issue":"11","key":"1267_CR124","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1185\/03007991003769241","volume":"26","author":"A Crucitti","year":"2010","unstructured":"Crucitti A, Zhang Qi, Nilsson M, Brecht S, Yang CR, Wernicke J. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis. Curr Med Res Opin. 2010;26(11):2579\u201388. https:\/\/doi.org\/10.1185\/03007991003769241.","journal-title":"Curr Med Res Opin"},{"key":"1267_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247595","author":"Y Cui","year":"2024","unstructured":"Cui Y, et al. The long-term cardiovascular risks of duloxetine use in older adults: a retrospective medical record-based adverse drug reaction assessment. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13247595.","journal-title":"J Clin Med"},{"issue":"12","key":"1267_CR126","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","volume":"154","author":"S Tesfaye","year":"2013","unstructured":"Tesfaye S, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2013a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616\u201325.","journal-title":"Pain"},{"issue":"8","key":"1267_CR127","first-page":"CD011091","volume":"2015","author":"HC Gallagher","year":"2015","unstructured":"Gallagher HC, et al. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(8):CD011091.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1267_CR128","first-page":"192","volume":"19","author":"N Razazian","year":"2014","unstructured":"Razazian N, et al. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014;19(3):192\u20138.","journal-title":"Neurosciences (Riyadh)"},{"issue":"6","key":"1267_CR129","first-page":"E705","volume":"16","author":"N Rudroju","year":"2013","unstructured":"Rudroju N, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):E705\u201314.","journal-title":"Pain Physician"},{"issue":"7","key":"1267_CR130","first-page":"CD008242","volume":"2015","author":"RA Moore","year":"2015","unstructured":"Moore RA, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(7):CD008242.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1267_CR131","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2337\/dc13-2291","volume":"37","author":"AI Vinik","year":"2014","unstructured":"Vinik AI, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302\u20139.","journal-title":"Diabetes Care"},{"key":"1267_CR132","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2147\/JPR.S190162","volume":"12","author":"U Freo","year":"2019","unstructured":"Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019;12:1537\u201351.","journal-title":"J Pain Res"},{"issue":"5","key":"1267_CR133","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1177\/08971900221087119","volume":"36","author":"S Goswami","year":"2023","unstructured":"Goswami S, et al. Gabapentin and opioids utilization in patients with diabetic neuropathy enrolled in Medicare (2012\u20132016): a cohort study. J Pharm Pract. 2023;36(5):1085\u201394.","journal-title":"J Pharm Pract"},{"issue":"6","key":"1267_CR134","first-page":"CD003726","volume":"6","author":"RM Duehmke","year":"2017","unstructured":"Duehmke RM, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD003726.","journal-title":"Cochrane Database Syst Rev"},{"key":"1267_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060801","author":"O Syed","year":"2023","unstructured":"Syed O, Jancic P, Knezevic NN. A review of recent pharmacological advances in the management of diabetes-associated peripheral neuropathy. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16060801.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1267_CR136","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.2147\/JPR.S481944","volume":"17","author":"L Kapural","year":"2024","unstructured":"Kapural L, et al. Safety and efficacy of axon therapy (SEAT study), utilizing magnetic peripheral nerve stimulation (mPNS) for treatment of neuropathic pain. J Pain Res. 2024;17:3167\u201374.","journal-title":"J Pain Res"},{"key":"1267_CR137","doi-asserted-by":"publisher","unstructured":"Brown L, et al. Safety and efficacy of magnetic peripheral nerve stimulation for treating painful diabetic neuropathy. Neuromodulation. 2025;30:S1094-7159(25)00138-2. https:\/\/doi.org\/10.1016\/j.neurom.2025.03.074.","DOI":"10.1016\/j.neurom.2025.03.074"},{"issue":"1","key":"1267_CR138","doi-asserted-by":"publisher","first-page":"10840","DOI":"10.1038\/s41467-024-55152-7","volume":"15","author":"N Gozzi","year":"2024","unstructured":"Gozzi N, et al. Wearable non-invasive neuroprosthesis for targeted sensory restoration in neuropathy. Nat Commun. 2024;15(1):10840.","journal-title":"Nat Commun"},{"key":"1267_CR139","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.2147\/JPR.S145999","volume":"11","author":"S Javed","year":"2018","unstructured":"Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res. 2018;11:1559\u201366.","journal-title":"J Pain Res"},{"key":"1267_CR140","doi-asserted-by":"publisher","unstructured":"Roikjer, J., et al., Diabetic peripheral neuropathy: emerging treatments of neuropathic pain and novel diagnostic methods. J Diabetes Sci Technol. 2024;19322968241279553. https:\/\/doi.org\/10.1177\/19322968241279553.","DOI":"10.1177\/19322968241279553"},{"issue":"2","key":"1267_CR141","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40200-024-01459-7","volume":"23","author":"A Elbeddini","year":"2024","unstructured":"Elbeddini A, et al. Assessing the efficacy of topical formulations in diabetic neuropathy: a narrative review. J Diabetes Metab Disord. 2024;23(2):1613\u201320.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"1267_CR142","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","volume":"18","author":"DM Simpson","year":"2017","unstructured":"Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42\u201353. https:\/\/doi.org\/10.1016\/j.jpain.2016.09.008.","journal-title":"J Pain"},{"issue":"1","key":"1267_CR143","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13287-024-04033-3","volume":"15","author":"SD Alizadeh","year":"2024","unstructured":"Alizadeh SD, et al. Human studies of the efficacy and safety of stem cells in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis. Stem Cell Res Ther. 2024;15(1):442.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1267_CR144","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1210\/er.2018-00107","volume":"40","author":"GJ Bonhof","year":"2019","unstructured":"Bonhof GJ, et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev. 2019;40(1):153\u201392.","journal-title":"Endocr Rev"},{"issue":"1","key":"1267_CR145","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41419-021-03407-2","volume":"12","author":"R Li","year":"2021","unstructured":"Li R, et al. Acidic fibroblast growth factor attenuates type 2 diabetes-induced demyelination via suppressing oxidative stress damage. Cell Death Dis. 2021;12(1):107.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1267_CR146","first-page":"271","volume":"4","author":"G Pittenger","year":"2003","unstructured":"Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp Diabesity Res. 2003;4(4):271\u201385.","journal-title":"Exp Diabesity Res"},{"issue":"17","key":"1267_CR147","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","volume":"284","author":"SC Apfel","year":"2000","unstructured":"Apfel SC, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000;284(17):2215\u201321.","journal-title":"JAMA"},{"issue":"5","key":"1267_CR148","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ymthe.2024.02.035","volume":"32","author":"M Blaszkiewicz","year":"2024","unstructured":"Blaszkiewicz M, Tao T, Mensah-Arhin K, Willows JW, Bates R, Huang W, et al. Gene therapy approaches for obesity-induced adipose neuropathy: device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose. Mol Ther. 2024;32(5):1407\u201324. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.035.","journal-title":"Mol Ther"},{"issue":"3","key":"1267_CR149","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/acupmed-2013-010495","volume":"32","author":"AP Garrow","year":"2014","unstructured":"Garrow AP, et al. Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupunct Med. 2014;32(3):242\u20139.","journal-title":"Acupunct Med"},{"key":"1267_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062103","author":"J Dietzel","year":"2023","unstructured":"Dietzel J, et al. Acupuncture in patients with diabetic peripheral neuropathy-related complaints: a randomized controlled clinical trial. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12062103.","journal-title":"J Clin Med"},{"key":"1267_CR151","unstructured":"Petersen, E.A., et al., High-frequency 10-kHz spinal cord stimulation provides long-term (24-month) improvements in diabetes-related pain and quality of life for patients with painful diabetic neuropathy. J Diabetes Sci Technol. 2024; p. 19322968241268547."},{"issue":"5","key":"1267_CR152","first-page":"263","volume":"42","author":"A Morton","year":"2013","unstructured":"Morton A. Topical nitrates in painful diabetic neuropathy. Aust Fam Physician. 2013;42(5):263.","journal-title":"Aust Fam Physician"},{"key":"1267_CR153","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40200-015-0217-3","volume":"14","author":"A Taheri","year":"2015","unstructured":"Taheri A, et al. The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy. J Diabetes Metab Disord. 2015;14:86.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"1267_CR154","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/s12889-025-21639-1","volume":"25","author":"Z Fan","year":"2025","unstructured":"Fan Z, et al. Analysis of risk factors for foot ulcers in diabetes patients with neurovascular complications. BMC Public Health. 2025;25(1):792.","journal-title":"BMC Public Health"},{"issue":"3","key":"1267_CR155","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3646","volume":"40","author":"DK Wukich","year":"2024","unstructured":"Wukich DK, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes Metab Res Rev. 2024;40(3):e3646.","journal-title":"Diabetes Metab Res Rev"},{"key":"1267_CR156","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-444-53480-4.00008-4","volume":"126","author":"AJ Boulton","year":"2014","unstructured":"Boulton AJ. Diabetic neuropathy and foot complications. Handb Clin Neurol. 2014;126:97\u2013107.","journal-title":"Handb Clin Neurol"},{"issue":"11","key":"1267_CR157","volume":"14","author":"J Karedath","year":"2022","unstructured":"Karedath J, et al. The impact of vitamin B12 supplementation on clinical outcomes in patients with diabetic neuropathy: a meta-analysis of randomized controlled trials. Cureus. 2022;14(11):e31783.","journal-title":"Cureus"},{"issue":"10","key":"1267_CR158","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1530\/EC-19-0382","volume":"8","author":"M Alvarez","year":"2019","unstructured":"Alvarez M, et al. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. Endocr Connect. 2019;8(10):1324\u20139.","journal-title":"Endocr Connect"},{"issue":"5","key":"1267_CR159","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/17474124.2023.2204229","volume":"17","author":"A Choudhury","year":"2023","unstructured":"Choudhury A, et al. Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2023;17(5):479\u201387.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01267-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01267-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:03:23Z","timestamp":1769702603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01267-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":159,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01267-5","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MD, SD and VD declare that they have no conflicts of interest of relevant to the contents of this manuscript. EBJ has received research and travel grants from Abbott, Astra Zeneca, Novo Nordisk, Menarini, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"MD, SD and VF wrote the first draft of the manuscript. EBJ provided critical review of the manuscript. All authors approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}